Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.1.15.1 - venom exonuclease

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acute Coronary Syndrome
Possible involvement of minor lysophospholipids in the increase in plasma lysophosphatidic acid in acute coronary syndrome.
Relationship between serum 5'-nucleotide phosphodiesterase activity and thrombophilia: enzyme activity in fetus and in patients with acute coronary syndrome.
Acute Lung Injury
Autotaxin and Endotoxin-Induced Acute Lung Injury.
Acute-On-Chronic Liver Failure
Autotaxin: An Early Warning Biomarker for Acute-on-chronic Liver Failure.
Adenomatous Polyps
Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers.
Alzheimer Disease
Autotaxin is Related to Metabolic Dysfunction and Predicts Alzheimer's Disease Outcomes.
Aneurysm
NSun2 regulates aneurysm formation by promoting autotaxin expression and T cell recruitment.
Aortic Valve Disease
Autotaxin and Lipoprotein Metabolism in Calcific Aortic Valve Disease.
Aortic Valve Stenosis
Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease.
Interaction of Autotaxin With Lipoprotein(a) in Patients With Calcific Aortic Valve Stenosis.
Arthralgia
Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.
Arthritis
A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid Levels in Plasma and the Site of Inflammation.
Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis.
Experimental arthritis. Pathogenic role of autotaxin and LPA.
Arthritis, Rheumatoid
Autotaxin and lysophospholipids in rheumatoid arthritis.
IL-1 beta- and IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA).
Performance of autotaxin as a serum marker for liver fibrosis.
Asthma
Leukocyte cyclic-3', 5'-nucleotide phosphodiesterase activity in human bronchial asthma.
Atherosclerosis
Source and Role of Intestinally-Derived Lysophosphatidic Acid in Dyslipidemia and Atherosclerosis.
Autoimmune Pancreatitis
Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis.
Biliary Atresia
Association between Promoter Hypomethylation and Overexpression of Autotaxin with Outcome Parameters in Biliary Atresia.
Hepatic autotaxin overexpression in infants with biliary atresia.
Impact of serum autotaxin level correlating with histological findings in biliary atresia.
Serum autotaxin levels correlate with hepatic dysfunction and severity in postoperative biliary atresia.
Brain Injuries
Autotaxin (NPP-2) in the brain: cell type-specific expression and regulation during development and after neurotrauma.
Modulation of LPA Receptor Expression in the Human Brain Following Neurotrauma.
Brain Injuries, Traumatic
Modulation of LPA Receptor Expression in the Human Brain Following Neurotrauma.
Brain Ischemia
Disrupted Blood-Brain Barrier and Mitochondrial Impairment by Autotaxin-Lysophosphatidic Acid Axis in Postischemic Stroke.
Brain Neoplasms
LPA1 receptor activation induces PKC? nuclear translocation in glioblastoma cells.
Breast Neoplasms
5'-Nucleotide phosphodiesterase isozyme-V as a marker for liver metastases in breast cancer patients.
Adipocyte biology in breast cancer: From silent bystander to active facilitator.
Adipokines as therapeutic targets in breast cancer treatment.
Association of autotaxin and lysophosphatidic acid receptor 3 with aggressiveness of human breast carcinoma.
Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae.
Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.
Evaluation of 5'-nucleotide phosphodiesterase isozyme-V as a predictor for liver metastasis in breast cancer patients.
Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells.
Expression of Autotaxin?Lysophosphatidate Signaling-Related Proteins in Breast Cancer with Adipose Stroma.
Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.
Identification of large-scale molecular changes of Autotaxin(ENPP2) knock-down by small interfering RNA in breast cancer cells.
Implications for breast cancer treatment from increased autotaxin production in adipose tissue after radiotherapy.
Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice.
Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
Inhibition of autotaxin with GLPG1690 increases the efficacy of radiotherapy and chemotherapy in a mouse model of breast cancer.
Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells.
Interaction of platelet-derived autotaxin with tumor integrin ?V?3 controls metastasis of breast cancer cells to bone.
Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest.
Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment.
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
Positron Emission Tomography Imaging of Autotaxin in Thyroid and Breast Cancer Models Using [18F]PRIMATX.
Role of Adipose Tissue-Derived Autotaxin, Lysophosphatidate Signaling, and Inflammation in the Progression and Treatment of Breast Cancer.
Serum ATX as a novel biomarker for breast cancer.
Stat3 mediates expression of autotaxin in breast cancer.
The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin.
Tumor-induced inflammation in mammary adipose tissue stimulates a vicious cycle of autotaxin expression and breast cancer progression.
Universal molecular beacon-based tracer system for real-time polymerase chain reaction.
Carcinogenesis
Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.
Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
Exocrine pancreatic carcinogenesis and autotaxin expression.
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.
Therapeutic Targeting of the Secreted Lysophospholipase D Autotaxin Suppresses Tuberous Sclerosis Complex-Associated Tumorigenesis.
[Complex of repair DNA polymerase beta with autonomous 3'-->5'-exonuclease shows increased accuracy of DNA synthesis]
Carcinoma
A nucleotide phosphodiesterase with preference for 2',5'-phosphodiester bonds from Ehrlich ascites carcinoma.
Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.
Association of autotaxin and lysophosphatidic acid receptor 3 with aggressiveness of human breast carcinoma.
Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer.
Increased serum autotaxin levels in hepatocellular carcinoma patients were caused by background liver fibrosis but not by carcinoma.
Metastatic uveal melanoma. Hepatic cell-surface enzymes, isoenzymes, and serum sialic acid levels in early metastatic disease.
Modification of ribonucleic acid by vitamin B6. 1. Specific interaction of pyridoxal 5'-phosphate with transfer ribonucleic acid.
Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression.
Short hairpin RNA targeting autotaxin reduces human gastric carcinoma AGS cell proliferative, migratory and invasive capabilities in vitro and causes tumor regression in vivo.
The significance of 5'-nucleotide phosphodiesterase isozymes in the diagnosis of liver carcinoma.
Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study.
[Mammalian plasma proteins bindings with single-stranded DNA; their effect on DNA polymerization and degradation reactions]
Carcinoma in Situ
Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study.
Carcinoma, Hepatocellular
5'-Nucleotide phosphodiesterase activity in rat hepatoma.
5'-Nucleotide phosphodiesterase and alkaline phosphatase in tumor cells: evidence for existence of novel species in the cytosol.
5'-nucleotide phosphodiesterase isoenzyme in patients with hepatitis B infection.
5'-Nucleotide phosphodiesterase isoenzyme pattern in the serum of human hepatoma.
5'-Nucleotide phosphodiesterase isozyme-V in health, in cancer, and in viral hepatitis.
5'-Nucleotide phosphodiesterase isozyme-V in hepatocellular carcinoma and other liver diseases.
Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma.
Autotaxin Expression in Hepatocellular Carcinoma.
Elevated Autotaxin and LPA Levels During Chronic Viral Hepatitis and Hepatocellular Carcinoma Associate with Systemic Immune Activation.
Expression of autotaxin mRNA in human hepatocellular carcinoma.
Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels.
Increased serum autotaxin levels in hepatocellular carcinoma patients were caused by background liver fibrosis but not by carcinoma.
Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer?
New abnormal isoenzyme of 5'-nucleotide phosphodiesterase in the serum of human hepatoma.
Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C.
Proteomics Based Identification of Autotaxin As An Anti-Hepatitis B Virus Factor and a Promoter of Hepatoma Cell Invasion and Migration.
The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer.
[A study on expression of autotaxin mRNA in hepatocellular carcinoma]
Carcinoma, Renal Cell
Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression.
Cardiomegaly
Autotaxin/lysophosphatidic acid signaling mediates obesity-related cardiomyopathy in mice and human subjects.
Cardiomyopathies
Adipose tissue-derived autotaxin causes cardiomyopathy in obese mice.
Autotaxin/lysophosphatidic acid signaling mediates obesity-related cardiomyopathy in mice and human subjects.
Cardiovascular Diseases
Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes.
Targeting the autotaxin - Lysophosphatidic acid receptor axis in cardiovascular diseases.
Cataract
Effect of postoperative corticosteroids on surgical outcome and aqueous autotaxin following combined cataract and microhook ab interno trabeculotomy.
Cholangiocarcinoma
Identification of B10, an alkaline phosphodiesterase of the apical plasma membrane of hepatocytes and biliary cells, in rat serum: increased levels following bile duct ligation and during the development of cholangiocarcinoma.
Cholangitis
Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis.
Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus.
Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).
Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.
Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis.
Cholangitis, Sclerosing
Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis.
Cholestasis
Is melatonin effective for pruritus caused by liver disease?
Liver: Potential of autotaxin as a diagnostic marker and therapeutic target for itch of cholestasis.
Mediators of pruritus during cholestasis.
Relationship between pruritus and autotaxin in intrahepatic cholestasis of pregnancy.
Role of the placenta in serum autotaxin elevation during maternal cholestasis.
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions.
The challenge of cholestatic pruritus.
The role of autotaxin and lysophosphatidic acid in pruritus of cholestasis.
[Pruritus in liver disease. Pathogenesis and treatment].
Cholestasis, Intrahepatic
Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy.
Relationship between pruritus and autotaxin in intrahepatic cholestasis of pregnancy.
Chondrocalcinosis
Expression of the murine plasma cell nucleotide pyrophosphohydrolase PC-1 is shared by human liver, bone, and cartilage cells. Regulation of PC-1 expression in osteosarcoma cells by transforming growth factor-beta.
Colitis
Autotaxin determines colitis severity in mice and is secreted by B cells in the colon.
Autotaxin stimulates LPA2 receptor in macrophages and exacerbates dextran sulfate sodium-induced acute colitis.
Deficiency of alkaline SMase enhances dextran sulfate sodium-induced colitis in mice with upregulation of autotaxin.
Colorectal Neoplasms
Immunohistochemical Detection of Autotaxin (ATX)/Lysophospholipase D (lysoPLD) in Submucosal Invasive Colorectal Cancer.
[Clinical study on serum 5'-nucleotide phosphodiesterase isoenzyme-V as a predictor of liver metastases in patients with gastric and colorectal cancers]
Coronary Artery Disease
Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease.
Dementia
Autotaxin expression is enhanced in frontal cortex of Alzheimer-type dementia patients.
Demyelinating Diseases
Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine.
Dermatitis, Atopic
Effects of Gintonin-Enriched Fraction in an Atopic Dermatitis Animal Model: Involvement of Autotaxin Regulation.
Increased lysophospholipase D activity of autotaxin in sera of patients with atopic dermatitis.
Is melatonin effective for pruritus caused by liver disease?
Serum Autotaxin Levels Correlate with Pruritus in Patients with Atopic Dermatitis.
Diabetes Mellitus
Performance of autotaxin as a serum marker for liver fibrosis.
Diabetes Mellitus, Type 2
Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression.
Diabetic Nephropathies
Serum Autotaxin Levels Are Associated with Proteinuria and Kidney Lesions in Japanese Type 2 Diabetic Patients with Biopsy-proven Diabetic Nephropathy.
Diabetic Retinopathy
Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy.
Encephalomyelitis
Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmune encephalomyelitis.
Genetic deletion of Autotaxin from CD11b+ cells decreases the severity of experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmune encephalomyelitis.
Genetic deletion of Autotaxin from CD11b+ cells decreases the severity of experimental autoimmune encephalomyelitis.
Endometrial Neoplasms
Autotaxin is a novel molecular identifier of type I endometrial cancer.
Autotaxin: A possible new biological marker of endometrial cancer.
Determination of cell cycle DNA and 5'-nucleotide phosphodiesterase in endometrial cancer.
The significance of the altered expression of lysophosphatidic acid receptors, autotaxin and phospholipase A2 as the potential biomarkers in type 1 endometrial cancer biology.
Endotoxemia
Inhibition of Autotaxin and Lysophosphatidic Acid Receptor 5 Attenuates Neuroinflammation in LPS-Activated BV-2 Microglia and a Mouse Endotoxemia Model.
Epiretinal Membrane
Expression of autotaxin and acylglycerol kinase in proliferative vitreoretinal epiretinal membranes.
Epstein-Barr Virus Infections
Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells.
Fatty Liver
Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
Performance of autotaxin as a serum marker for liver fibrosis.
Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.
Fibromyalgia
CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia.
Fibrosarcoma
Autotaxin promotes the expression of matrix metalloproteinase-3 via activation of the MAPK cascade in human fibrosarcoma HT-1080 cells.
Gastrointestinal Diseases
Diagnostic value of 5'-nucleotide phosphodiesterase isozyme-V for detection of liver metastasis in patients with gastro-intestinal cancer.
[Significance of serum autotaxin activity in gastrointestinal disease]
Gastrointestinal Neoplasms
Detection of liver metastases with 5'-nucleotide phosphodiesterase isozyme-V in gastrointestinal cancer patients.
Serum 5'-nucleotide phosphodiesterase as a predictor of hepatic metastases in gastrointestinal cancer.
Glaucoma
Crosstalk between transforming growth factor ?-2 and Autotaxin in trabecular meshwork and different subtypes of glaucoma.
Increased aqueous autotaxin and lysophosphatidic acid levels are potential prognostic factors after trabeculectomy in different types of glaucoma.
Role of the autotaxin-lysophosphatidic acid axis in glaucoma, aqueous humor drainage and fibrogenic activity.
Glaucoma, Open-Angle
Aqueous autotaxin and TGF-?s are promising diagnostic biomarkers for distinguishing open-angle glaucoma subtypes.
Role of the autotaxin-lysophosphatidic acid axis in glaucoma, aqueous humor drainage and fibrogenic activity.
Glioblastoma
Autotaxin Inhibition with PF-8380 Enhances the Radiosensitivity of Human and Murine Glioblastoma Cell Lines.
Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
LPA1 receptor activation induces PKC? nuclear translocation in glioblastoma cells.
Glioma
5'-nucleotide phosphodiesterase activity of floxuridine-resistant mouse glioma.
Autotaxin and LPA Receptors Represent Potential Molecular Targets for the Radiosensitization of Murine Glioma through Effects on Tumor Vasculature.
Autotaxin: a secreted autocrine/paracrine factor that promotes glioma invasion.
PF-8380 and closely related analogs: synthesis and structure-activity relationship towards autotaxin inhibition and glioma cell viability.
Glucose Intolerance
Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression.
Graves Disease
Serum autotaxin levels are associated with Graves' disease.
Hepatitis
5'-Nucleotide phosphodiesterase isozyme-V in health, in cancer, and in viral hepatitis.
Elevated Autotaxin and LPA Levels During Chronic Viral Hepatitis and Hepatocellular Carcinoma Associate with Systemic Immune Activation.
Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer?
Hepatitis B
5'-nucleotide phosphodiesterase isoenzyme in patients with hepatitis B infection.
5'-Nucleotide phosphodiesterase isozyme-V in health, in cancer, and in viral hepatitis.
Performance of autotaxin as a serum marker for liver fibrosis.
Hepatitis B, Chronic
Performance of autotaxin as a serum marker for liver fibrosis.
Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection.
Hepatitis C
Autotaxin and vascular endothelial growth factor receptor-2 and -3 are related to vascular development during the progression of chronic viral hepatitis C.
Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer?
Performance of autotaxin as a serum marker for liver fibrosis.
Hepatitis C, Chronic
Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C.
Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C.
Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C.
Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C.
Serum Autotaxin Concentrations Reflect Changes in Liver Stiffness and Fibrosis After Antiviral Therapy in Patients with Chronic Hepatitis C.
Herpes Simplex
Contribution of the 3'- to 5'-exonuclease activity of herpes simplex virus type 1 DNA polymerase to the fidelity of DNA synthesis.
Herpes simplex virus type 1 single-strand DNA binding protein ICP8 enhances the nuclease activity of the UL12 alkaline nuclease by increasing its processivity.
HIV Infections
During HCV and HCV-HIV infection elevated plasma Autotaxin is associated with LPA and markers of immune activation that normalize during IFN-free HCV therapy.
Hodgkin Disease
Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells.
Hypertension, Pregnancy-Induced
Serum autotaxin measurements in pregnant women: Application for the differentiation of normal pregnancy and pregnancy-induced hypertension.
Hypertrophy, Left Ventricular
Adipose tissue-derived autotaxin causes cardiomyopathy in obese mice.
Hypoalbuminemia
Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation.
Hypotension
Snake venom NAD glycohydrolases: primary structures, genomic location, and gene structure.
Idiopathic Pulmonary Fibrosis
Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae.
Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis.
CREB-dependent LPA-induced signaling initiates a pro-fibrotic feedback loop between small airway basal cells and fibroblasts.
Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis.
Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.
Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).
Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.
Infections
5'-nucleotide phosphodiesterase isoenzyme in patients with hepatitis B infection.
5'-Nucleotide phosphodiesterase isozyme-V in health, in cancer, and in viral hepatitis.
During HCV and HCV-HIV infection elevated plasma Autotaxin is associated with LPA and markers of immune activation that normalize during IFN-free HCV therapy.
Serum Autotaxin Concentrations Reflect Changes in Liver Stiffness and Fibrosis After Antiviral Therapy in Patients with Chronic Hepatitis C.
The deoxyribonuclease induced after infection of Escherichia coli by bacteriophage T5. I. Characterization of the enzyme as a 5'-exonuclease.
Inflammatory Bowel Diseases
Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis.
Pharmacological Characterization of a Potent Inhibitor of Autotaxin in Animal Models of Inflammatory Bowel Disease and Multiple Sclerosis.
Insulin Resistance
Blocking gp130 signaling suppresses autotaxin expression in adipocytes and improves insulin sensitivity in diet-induced obesity.
Identification of Ganglioside GM3 Molecular Species in Human Serum Associated with Risk Factors of Metabolic Syndrome.
Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression.
Ischemic Stroke
Disrupted Blood-Brain Barrier and Mitochondrial Impairment by Autotaxin-Lysophosphatidic Acid Axis in Postischemic Stroke.
Leiomyoma
Role of lysophosphatidic acid in the regulation of uterine leiomyoma cell proliferation by phospholipase D and autotaxin.
Leukemia
Inhibition of the 3' --> 5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA.
Leukemia, Myeloid, Acute
Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation.
Liver Cirrhosis
Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C.
Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C.
Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis.
Autotaxin as a novel serum marker of liver fibrosis.
Autotaxin in liver fibrosis.
Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
Carvacrol hinders the progression of hepatic fibrosis via targeting autotaxin and thioredoxin in thioacetamide-induced liver fibrosis in rat.
Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis.
Effect of histidine on autotaxin activity in experimentally induced liver fibrosis.
Hepatocyte autotaxin expression promotes liver fibrosis and cancer.
Impact of serum autotaxin level correlating with histological findings in biliary atresia.
Increased serum autotaxin levels in hepatocellular carcinoma patients were caused by background liver fibrosis but not by carcinoma.
Performance of autotaxin as a serum marker for liver fibrosis.
Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.
Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.
Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis--a prospective cohort study.
Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection.
Usefulness of autotaxin for the complications of liver cirrhosis.
Liver Cirrhosis, Biliary
Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis.
Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus.
Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).
Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.
Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis.
Liver Diseases
5'-Nucleotide phosphodiesterase isozyme-V in hepatocellular carcinoma and other liver diseases.
Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis.
Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
Is melatonin effective for pruritus caused by liver disease?
Performance of autotaxin as a serum marker for liver fibrosis.
Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.
Role of the placenta in serum autotaxin elevation during maternal cholestasis.
Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.
Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases.
Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.
The correlation between the autotaxin enzyme and pruritus in Egyptian patients suffering from chronic liver disease.
Liver Neoplasms
5'-Nucleotide phosphodiesterase isoenzyme and hepatic cancer in NCI-Mayo Clinic panel sera.
An isoenzyme of 5'-nucleotide phosphodiesterase and alpha-fetoprotein in human hepatic cancer patient sera.
New abnormal isoenzyme of 5'-nucleotide phosphodiesterase in the serum of human hepatoma.
The significance of new abnormal isoenzymes of 5'-nucleotide phosphodiesterase in the diagnosis of human liver cancer.
Liver Neoplasms, Experimental
A surface 3'-exonuclease of Novikoff hepatoma ascites cells.
Lung Diseases, Interstitial
Therapeutic Potential of Autotaxin Inhibitors in Treatment of Interstitial Lung Diseases.
Lung Injury
Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Lung Neoplasms
Autotaxin expression in non-small-cell lung cancer.
Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D.
Lupus Nephritis
Higher serum levels of autotaxin and phosphatidylserine-specific phospholipase A1 in patients with lupus nephritis.
Lymphoma
A novel tumor-associated molecular species of 5'-nucleotide phosphodiesterase.
Autotaxin and soluble IL-2 receptor concentrations in cerebrospinal fluids are useful for the diagnosis of central nervous system invasion caused by haematological malignancies.
Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells.
Lymphoma, Follicular
Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma.
Lymphoma, Large-Cell, Anaplastic
Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells.
Mastocytoma
Blocked 5'-termini in the fragments of chromosomal DNA produced in cells exposed to the antitumor drug 4'-[(9-acridinyl)-amino]methanesulphon-m-anisidide (mAMSA).
Melanoma
Association between serum autotaxin or phosphatidylserine-specific phospholipase A1 levels and melanoma.
Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis.
Autotaxin is an N-linked glycoprotein but the sugar moieties are not needed for its stimulation of cellular motility.
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.
Autotaxin stimulates urokinase-type plasminogen activator expression through phosphoinositide 3-kinase-Akt-nuclear [corrected] factor kappa B signaling cascade in human melanoma cells.
Autotaxin: its role in biology of melanoma cells and as a pharmacological target.
Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.
Galectin-3 Contributes to Melanoma Growth and Metastasis via Regulation of NFAT1 and Autotaxin.
Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.
Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest.
NFAT1 directly regulates IL-8 and MMP-3 to promote melanoma tumor growth and metastasis.
Reduced expression of autotaxin predicts survival in uveal melanoma.
Suppression of metastasis of intravenously-inoculated B16/F10 melanoma cells by the novel ginseng-derived ingredient, gintonin: involvement of autotaxin inhibition.
Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid.
The N-terminal hydrophobic sequence of autotaxin (ENPP2) functions as a signal peptide.
Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.
Mesothelioma
Autotaxin signaling governs phenotypic heterogeneity in visceral and parietal mesothelia.
Metabolic Diseases
Identification of Ganglioside GM3 Molecular Species in Human Serum Associated with Risk Factors of Metabolic Syndrome.
Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease.
Migraine Disorders
Association of brain-derived neurotrophic factor and nerve growth factor gene polymorphisms with susceptibility to migraine.
Multiple Sclerosis
A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid Levels in Plasma and the Site of Inflammation.
Increased autotaxin activity in multiple sclerosis.
Pharmacological Characterization of a Potent Inhibitor of Autotaxin in Animal Models of Inflammatory Bowel Disease and Multiple Sclerosis.
Musculoskeletal Pain
Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.
Myocardial Infarction
Autotaxin inhibition reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction.
Neoplasm Metastasis
5'-Nucleotide phosphodiesterase isozyme-V as a marker for liver metastases in breast cancer patients.
Adipokines as therapeutic targets in breast cancer treatment.
Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D.
Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis.
Autotaxin Implication in Cancer Metastasis and Autoimunne Disorders: Functional Implication of Binding Autotaxin to the Cell Surface.
Autotaxin stimulates urokinase-type plasminogen activator expression through phosphoinositide 3-kinase-Akt-nuclear [corrected] factor kappa B signaling cascade in human melanoma cells.
Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.
Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.
Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo.
Detection of hepatic metastases with serum 5'-nucleotide phosphodiesterase isoenzymes.
Detection of liver metastases with 5'-nucleotide phosphodiesterase isozyme-V in gastrointestinal cancer patients.
Diagnostic value of 5'-nucleotide phosphodiesterase isozyme-V for detection of liver metastasis in patients with gastro-intestinal cancer.
Domain interplay mediated by an essential disulfide linkage is critical for the activity and secretion of the metastasis-promoting enzyme autotaxin.
Evaluation of 5'-nucleotide phosphodiesterase isozyme-V as a predictor for liver metastasis in breast cancer patients.
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.
Galectin-3 Contributes to Melanoma Growth and Metastasis via Regulation of NFAT1 and Autotaxin.
Genetic basis of human breast cancer metastasis.
Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.
Identification of Potent In Vivo Autotaxin Inhibitors that Bind to Both Hydrophobic Pockets and Channels in the Catalytic Domain.
Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice.
Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
Inhibition of autotaxin with GLPG1690 increases the efficacy of radiotherapy and chemotherapy in a mouse model of breast cancer.
Interaction of platelet-derived autotaxin with tumor integrin ?V?3 controls metastasis of breast cancer cells to bone.
Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer.
Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest.
NFAT1 directly regulates IL-8 and MMP-3 to promote melanoma tumor growth and metastasis.
Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer.
Platelets, autotaxin and lysophosphatidic acid signalling: win-win factors for cancer metastasis.
Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance.
Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy.
Serum 5'-nucleotide phosphodiesterase as a predictor of hepatic metastases in gastrointestinal cancer.
Serum ATX as a novel biomarker for breast cancer.
Suppression of metastasis of intravenously-inoculated B16/F10 melanoma cells by the novel ginseng-derived ingredient, gintonin: involvement of autotaxin inhibition.
Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid.
[Clinical study on serum 5'-nucleotide phosphodiesterase isoenzyme-V as a predictor of liver metastases in patients with gastric and colorectal cancers]
Neoplasms
5'-nucleotide phosphodiesterase activity of floxuridine-resistant mouse glioma.
5'-Nucleotide phosphodiesterase and alkaline phosphatase in tumor cells: evidence for existence of novel species in the cytosol.
5'-Nucleotide phosphodiesterase isozyme-V in health, in cancer, and in viral hepatitis.
A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid Levels in Plasma and the Site of Inflammation.
A nucleotide phosphodiesterase with preference for 2',5'-phosphodiester bonds from Ehrlich ascites carcinoma.
Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers.
Adipocyte biology in breast cancer: From silent bystander to active facilitator.
Altered activity of lysophospholipase D, which produces bioactive lysophosphatidic acid and choline, in serum from women with pathological pregnancy.
An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases.
Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer.
Association of autotaxin and lysophosphatidic acid receptor 3 with aggressiveness of human breast carcinoma.
ATX-LPA receptor axis in inflammation and cancer.
Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor.
Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis.
Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae.
Autotaxin and LPA receptor signaling in cancer.
Autotaxin and LPA Receptors Represent Potential Molecular Targets for the Radiosensitization of Murine Glioma through Effects on Tumor Vasculature.
Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis.
Autotaxin and soluble IL-2 receptor concentrations in cerebrospinal fluids are useful for the diagnosis of central nervous system invasion caused by haematological malignancies.
Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p.
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production.
Autotaxin Implication in Cancer Metastasis and Autoimunne Disorders: Functional Implication of Binding Autotaxin to the Cell Surface.
Autotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions.
Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer.
Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation.
Autotaxin signaling governs phenotypic heterogeneity in visceral and parietal mesothelia.
Autotaxin stimulates urokinase-type plasminogen activator expression through phosphoinositide 3-kinase-Akt-nuclear [corrected] factor kappa B signaling cascade in human melanoma cells.
Autotaxin upregulated by STAT3 activation contributes to invasion in pancreatic neuroendocrine neoplasms.
Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.
Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer.
Autotaxin, tumor motility-stimulating exophosphodiesterase.
Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
Autotaxin.
Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.
Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.
Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo.
cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases.
Characterization of a monoclonal antibody defining a macrophage activation-specific cell surface antigen.
Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells.
Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation.
Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase.
Detection of liver metastases with 5'-nucleotide phosphodiesterase isozyme-V in gastrointestinal cancer patients.
Diagnostic value of 5'-nucleotide phosphodiesterase isozyme-V for detection of liver metastasis in patients with gastro-intestinal cancer.
Domain interplay mediated by an essential disulfide linkage is critical for the activity and secretion of the metastasis-promoting enzyme autotaxin.
Expression of autotaxin and acylglycerol kinase in prostate cancer: association with cancer development and progression.
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.
Expression of proteins related to autotaxin-lysophosphatidate signaling in thyroid tumors.
Expression, regulation and function of autotaxin in thyroid carcinomas.
Fluorometric assay of serum 5'-nucleotide phosphodiesterase in normal humans and cancer patients.
Galectin-3 Contributes to Melanoma Growth and Metastasis via Regulation of NFAT1 and Autotaxin.
Hepatocyte autotaxin expression promotes liver fibrosis and cancer.
Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase.
Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization.
Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice.
Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
Inhibition of autotaxin with GLPG1690 increases the efficacy of radiotherapy and chemotherapy in a mouse model of breast cancer.
Interaction of platelet-derived autotaxin with tumor integrin ?V?3 controls metastasis of breast cancer cells to bone.
Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer?
L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin.
Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer.
Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors.
Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest.
Lysophosphatidic acid converts monocytes into macrophages in both mice and humans.
Lysophosphatidic acid reverses Temsirolimus-induced changes in lipid droplets and mitochondrial networks in renal cancer cells.
Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases.
Lysophospholipids in the limelight: autotaxin takes center stage.
Macrophage activation by trehalose dimycolate requirement for an expression signal in vitro for antitumoral activity; biochemical markers distinguishing primed and fully activated macrophages.
Microarray analysis identifies Autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun.
Neural cell surface differentiation antigen gp130(RB13-6) induces fibroblasts and glioma cells to express astroglial proteins and invasive properties.
Non-invasive imaging of tumors by monitoring autotaxin activity using an enzyme-activated near-infrared fluorogenic substrate.
Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer.
Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity.
Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer.
Platelets, autotaxin and lysophosphatidic acid signalling: win-win factors for cancer metastasis.
Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D.
Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells.
Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance.
Role of autotaxin in cancer stem cells.
Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy.
Role of the autotaxin-lysophosphatidic acid axis in glaucoma, aqueous humor drainage and fibrogenic activity.
Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma.
Short hairpin RNA targeting autotaxin reduces human gastric carcinoma AGS cell proliferative, migratory and invasive capabilities in vitro and causes tumor regression in vivo.
Stimulation of several functional properties of macrophages after injection of a suspension of killed Streptococci.
Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin.
Structural characteristics of lysophosphatidic acid biological targets.
Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling.
Synthesis and Activity of a Novel Autotaxin Inhibitor-Icodextrin Conjugate.
The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin.
The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer.
The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site.
The role of autotaxin and other motility stimulating factors in the regulation of tumor cell motility.
[Clinical significance of 5'-nucleotide phosphodiesterase isoenzyme-V assay as a tumor marker]
[Elucidation of the functional roles of lysophospholipid mediators and its application in laboratory medicine]
[Lysophosphatidic acid and malignant neoplasms].
[Ratio of 3' --> 5'-exonuclease and DNA-polymerase activities in normal and cancer cells of rodents and humans].
Neuralgia
Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain.
CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia.
Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain.
Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis.
Lysophosphatidic acid is associated with neuropathic pain intensity in humans: An exploratory study.
Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid.
Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.
Neuroblastoma
Constitutive autotaxin transcription by Nmyc-amplified and non-amplified neuroblastoma cells is regulated by a novel AP-1 and SP-mediated mechanism and abrogated by curcumin.
Retinoic acid-induced expression of autotaxin in N-myc-amplified neuroblastoma cells.
Neuroinflammatory Diseases
Inhibition of Autotaxin and Lysophosphatidic Acid Receptor 5 Attenuates Neuroinflammation in LPS-Activated BV-2 Microglia and a Mouse Endotoxemia Model.
Non-alcoholic Fatty Liver Disease
Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
Performance of autotaxin as a serum marker for liver fibrosis.
Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.
Obesity
Adipose-derived autotaxin regulates inflammation and steatosis associated with diet-induced obesity.
Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice.
Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity.
Blocking gp130 signaling suppresses autotaxin expression in adipocytes and improves insulin sensitivity in diet-induced obesity.
Depot-specific regulation of autotaxin with obesity in human adipose tissue.
Diet-regulated behavior: FVB/N mice fed a lean diet exhibit increased nocturnal bouts of aggression between littermates.
Pro-fibrotic activity of lysophosphatidic acid in adipose tissue: in vivo and in vitro evidence.
The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer.
Obesity, Morbid
Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity.
Osteoarthritis
Autotaxin Inhibitors May Treat Pain and Osteoarthritis.
Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.
Osteoarthritis, Knee
Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.
Plasma and synovial fluid autotaxin correlate with severity in knee osteoarthritis.
Ovarian Neoplasms
Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells.
Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
Dendrimer Conjugate of [4-(Tetradecanoylamino)benzyl]phosphonic Acid (S32826) as an Autotaxin Inhibitor.
New strategies for the treatment of ovarian cancer.
Positive Feedback between Vascular Endothelial Growth Factor-A and Autotaxin in Ovarian Cancer Cells.
Serum Autotaxin is not a Useful Biomarker for Ovarian Cancer.
Synthesis and Activity of a Novel Autotaxin Inhibitor-Icodextrin Conjugate.
Pancreatic Neoplasms
A FATal Combination: Fibroblast-Derived Lipids and Cancer-Derived Autotaxin Promote Pancreatic Cancer Growth.
Autotaxin in ascites promotes peritoneal dissemination in pancreatic cancer.
Specific increase in serum autotaxin activity in patients with pancreatic cancer.
The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer.
Paralysis
Snake venom NAD glycohydrolases: primary structures, genomic location, and gene structure.
Pneumonia
A role for bronchial epithelial autotaxin in ventilator-induced lung injury.
Pre-Eclampsia
Maternal serum autotaxin levels in early- and late-onset preeclampsia.
Placental autotaxin expression is diminished in women with pre-eclampsia.
Placental expression of lysophosphatidic acid receptors in normal pregnancy and preeclampsia.
Prostatic Neoplasms
Expression of autotaxin and acylglycerol kinase in prostate cancer: association with cancer development and progression.
Proteinuria
Serum Autotaxin Levels Are Associated with Proteinuria and Kidney Lesions in Japanese Type 2 Diabetic Patients with Biopsy-proven Diabetic Nephropathy.
Pruritus
Advances in pathogenesis and management of pruritus in cholestasis.
Alterations in Skin Microbiomes of Patients With Cirrhosis.
Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy.
Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus.
Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).
Cutting-Edge Issues in Primary Biliary Cirrhosis.
Effect of Plasmapheresis on Cholestatic Pruritus and Autotaxin Activity During Pregnancy.
Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
Is melatonin effective for pruritus caused by liver disease?
Lysophosphatidic acid activates satellite glia cells and Schwann cells.
Lysophosphatidic acid is a potential mediator of cholestatic pruritus.
Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum.
Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.
Refractory pruritus in primary biliary cirrhosis.
Relationship between pruritus and autotaxin in intrahepatic cholestasis of pregnancy.
Serum Autotaxin Activity Correlates With Pruritus in Pediatric Cholestatic Disorders.
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions.
Serum Autotaxin Levels Correlate with Pruritus in Patients with Atopic Dermatitis.
The challenge of cholestatic pruritus.
The correlation between the autotaxin enzyme and pruritus in Egyptian patients suffering from chronic liver disease.
The role of autotaxin and lysophosphatidic acid in pruritus of cholestasis.
Pulmonary Disease, Chronic Obstructive
Metabolomics analysis identifies sex-associated metabotypes of oxidative stress and the autotaxin-lysoPA axis in COPD.
Pulmonary Fibrosis
Autotaxin in Pathophysiology and Pulmonary Fibrosis.
Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
Pulmonary Autotaxin Expression Contributes to the Pathogenesis of Pulmonary Fibrosis.
Renal Insufficiency, Chronic
Performance of autotaxin as a serum marker for liver fibrosis.
Reperfusion Injury
Autotaxin inhibition attenuates endothelial permeability after ischemia-reperfusion injury.
Respiratory Distress Syndrome
Autotaxin levels in serum and bronchoalveolar lavage fluid are associated with inflammatory and fibrotic biomarkers and the clinical outcome in patients with acute respiratory distress syndrome.
Retinal Degeneration
Electron microscopic histochemical studies of cyclic 3', 5'-nucleotide phosphodiesterase in the developing retina of normal mice and mice with hereditary retinal degeneration.
Retinal Vein Occlusion
LYSOPHOSPHATIDIC ACIDS AND AUTOTAXIN IN RETINAL VEIN OCCLUSION.
Sarcoma
Control of breakdown of the polyadenylate sequence in mammalian polyribosomes: role of poly(adenylic acid)-protein interactions.
Nucleases and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in murine sarcoma virus (Moloney)-infected mice.
Scleroderma, Systemic
Antifibrotic effects of 2-carba cyclic phosphatidic acid (2ccPA) in systemic sclerosis: contribution to the novel treatment.
Sepsis
Alteration of Lysophosphatidylcholine-Related Metabolic Parameters in the Plasma of Mice with Experimental Sepsis.
Autotaxin Activity Predicts 30 Day Mortality in Sepsis Patients and Correlates With Platelet Count and Vascular Dysfunction.
Stroke
Disrupted Blood-Brain Barrier and Mitochondrial Impairment by Autotaxin-Lysophosphatidic Acid Axis in Postischemic Stroke.
Teratocarcinoma
Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells.
Thrombophilia
Relationship between serum 5'-nucleotide phosphodiesterase activity and thrombophilia: enzyme activity in fetus and in patients with acute coronary syndrome.
Thrombosis
Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis.
Thyroid Cancer, Papillary
Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer.
Thyroid Neoplasms
Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer.
Expression, regulation and function of autotaxin in thyroid carcinomas.
Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
Significance of autotaxin activity and overexpression in comparison to soluble intercellular adhesion molecule in thyroid cancer.
The cellular localization of autotaxin impacts on its biological functions in human thyroid carcinoma cells.
Tuberculosis
Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis.
Simultaneous identification of Mycobacterium genus and Mycobacterium tuberculosis complex in clinical samples by 5'-exonuclease fluorogenic PCR.
Tuberous Sclerosis
Therapeutic Targeting of the Secreted Lysophospholipase D Autotaxin Suppresses Tuberous Sclerosis Complex-Associated Tumorigenesis.
Ventilator-Induced Lung Injury
A role for bronchial epithelial autotaxin in ventilator-induced lung injury.
Virus Diseases
Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
Nucleases and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in murine sarcoma virus (Moloney)-infected mice.
Werner Syndrome
Coordinate action of the helicase and 3' to 5' exonuclease of Werner syndrome protein.
Wilms Tumor
Fluorescent 5'-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias.